Novel Rheumatoid Arthritis Drug Tops SPT Week in Review

Article

Top news of the week from Specialty Pharmacy Times.

5. FDA Approves Antibiotic for Complicated Intra-Abdominal Infections

Eravacycline is a tetracycline-class antibacterial injection that has demonstrated potent activity against multidrug-resistant pathogens. Read more.

4. Study: Daily Aspirin Did Not Reduce Risk of First Heart Attack, Stroke

Daily aspirin did not reduce the occurrence of major cardiovascular events a study of more than 12,500 participants considered to be at risk. Read more.

3. Combo Treatment Effectively Cures Hepatitis C in Liver Transplant Recipients

Study shows the safety and efficacy of treatment with sofosbuvir and velpatasvir in adults with recurrent chronic genotypes 1-4 HCV infection after liver transplant. Read more.

2. CMS to Implement Indication-Based Formulary Design for Medicare Part D Plans

Medicare Part D plans will be given flexibility to tailor on-formulary drug coverage based on specific indications. Read more.

1. Novel Rheumatoid Arthritis Therapy Effective in Phase 3 Study

New drug could serve as a potential treatment option for patients who have shown an inadequate response to conventional disease-modifying drugs. Read more.

Related Videos
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Krakenimages.com | stock.adobe.com
Human brain digital illustration. Electrical activity, flashes, and lightning on a blue background. | Image Credit: Siarhei - stock.adobe.com
Physician and kidneys
Image credit: gamjai - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.